



(51) International Patent Classification:

C07D 489/12 (2006.01) **A61P 25/04** (2006.01)
A61K 31/485 (2006.01)

(21) International Application Number:

PCT/IB2011/002208

(22) International Filing Date:

20 September 2011 (20.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/384,912 21 September 2010 (21.09.2010) US
61/503,674 1 July 2011 (01.07.2011) US

(71) Applicant (for all designated States except US): **PURDUE PHARMA L.P.** [US/US]; One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901-3431 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KYLE, Donald, J.** [US/US]; 173 N. Main Street, Yardley, PA 19067 (US). **TAFESSE, Laykea** [US/US]; 11 Abington Lane, Robbinsville, NJ 08691 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: BUPRENORPHINE ANALOGS



(57) **Abstract:** The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R^1 , R^2 , R^8 , R^{3a} , R^{3b} , G, X, Z and Y are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.